Anti-Influenza-A-Hämagglutinin-Rekombinanter Antikörper (Diridavumab (CR6261)) – Reguläre Charge (keine Endotoxinentfernung), SDS-PAGE>95 %, PE, 1 mg
Anti-Influenza A hemagglutinin Recombinant Antibody (Diridavumab (CR6261)) -Regular Batch (No Endotoxin Removal), SDS-PAGE>95%, PE, 1 mg
